Search Results for: space

Weekly reads: stem cell-assisted IVF, Takeda MSC trial, reporters getting stem cells

/ / 1 Comment
stem cell-assisted IVF, Dina Radenkovic, Gameto

There’s been much discussion about issues related to stem cells in the reproductive space such as human embryo models and differentiating stem cells into gametes, but there’s also interest in stem cell-assisted IVF. In this kind of method, stem cells are employed to make tissue cells such as ovarian stromal cells to support production of […]

Weekly reads: stem cell-assisted IVF, Takeda MSC trial, reporters getting stem cells Read More »

Weekly reads: stem cells for epilepsy from Neurona Therapeutics, diabetes, contagious cancer

/ / 2 Comments
Neurona Therapeutics, stem cells for epilepsy

People often ask me what are the most promising stem cell therapies in development and new data suggest we should add stem cells for epilepsy to the list based on work by Neurona Therapeutics. I’ll start off the weekly recommended reads with this new mouse paper on cell therapy for epilepsy. Neurona Therapeutics: stem cells

Weekly reads: stem cells for epilepsy from Neurona Therapeutics, diabetes, contagious cancer Read More »

FDA warns Neil Riordan U.S. perinatal firm Signature Biologics

/ / Leave a Comment
Signature Biologics, Neil Riordan

Neil Riordan may be most well-known for running the Panama stem cell clinic called simply enough the Stem Cell Institute, but he also has a U.S. firm Signature Biologics. The Panama  clinic sells unproven umbilical cord cells grown in a lab for a host of medical conditions. I’ve had many concerns about it over the

FDA warns Neil Riordan U.S. perinatal firm Signature Biologics Read More »

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell

/ / 11 Comments
Athersys stock, Athersys, stem cell stocks

I’ve been following 24 stem cell stocks for a few years. I haven’t invested in them or any others recently, but rather just find them interesting. How are these doing in 2023? Mostly not great. In some cases, it is downright disastrous. Let’s take a quick look at four stocks very much in the news over

Lessons from 4 stem cell stocks that tanked: Celularity, Athersys, Mesoblast, BrainStorm Cell Read More »

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up?

/ / 3 Comments
Burst Biologics, Christopher Jones

The New York Times just broke a story on Burst Biologics and Weill Cornell that fits with long-standing troubling questions about regenerative biologics producers. The story also bears on the doctors and hospitals like Weill Cornell that were or are customers of the suppliers. Further, what is the FDA’s role in all of this? The

Burst Biologics unapproved biologic used by Weill Cornell: was there a cover-up? Read More »

Defining epigenetic reprogramming, cellular reprogramming & rejuvenation

/ / Leave a Comment
epigenetic reprogramming

Epigenetic reprogramming is a term used in cell biology that is increasingly ending up in news stories too. Unfortunately, some folks, especially in the cellular rejuvenation and anti-aging space, are getting this term and other things confused. Just to start off, epigenetic reprogramming does not specifically mean cellular rejuvenation. The goal of today’s post is

Defining epigenetic reprogramming, cellular reprogramming & rejuvenation Read More »

Weekly reads: big Retraction Watch news, stem cells & metastasis, an FDA approval, Iowa AG sues clinic

/ / Leave a Comment
Retraction watch

Retraction Watch has been a great resource for those of us who have been following research misconduct. They widely cover and conduct research on retractions, corrections, and other developments in this space. Unfortunately, there’s been plenty to write about even just within the stem cell and cell therapy arena, which is my primary interest. Think

Weekly reads: big Retraction Watch news, stem cells & metastasis, an FDA approval, Iowa AG sues clinic Read More »

FDA warns more perinatal cell therapy firms: RenatiLabs & Cell Genuity

/ / 7 Comments
Dr. Leonid Macheret, FDA warning

Starting last year the FDA has focused much of its cell therapy oversight resources on birth-related firms, including both clinics and suppliers. The latest warnings went to RenatiLabs & Cell Genuity. Warnings to unproven perinatal cell therapy firms Earlier this summer the agency warned Regenative Labs. There have been quite a few letters to others in this

FDA warns more perinatal cell therapy firms: RenatiLabs & Cell Genuity Read More »

Is DNA methylation destiny? Diving into new epigenetic clock research

/ / 1 Comment

I’ve been thinking more about the steady stream of epigenetic clock research out there.  How convincing is the research on such clocks? Do they tightly relate to human biological age?  The related notion of turning back such hypothetical clocks to reverse aging is exciting but controversial. It doesn’t help that some are hyping all of

Is DNA methylation destiny? Diving into new epigenetic clock research Read More »